36 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
Exhibit 99.1
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
CBP-201 in Adult Patients with Chronic Rhinosinusitis … ” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
in Healthy Adult Subjects
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
SAN DIEGO … ”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through … is a chronic inflammatory skin disease that significantly impacts patients’ quality of life, and its prevalence in China is increasing, leading
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic … of the potential of CBP-201 in other indications currently being studied, including moderate-to-severe persistent asthma and chronic rhinosinusitis
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
17 May 21
Connect Biopharma Announces First
5:27pm
” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through … patients with moderate-to-severe persistent asthma (NCT04773678) and is in development for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP
6-K
EX-99.1
te8 2f1xktu
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.3
x0g8 oce0qzjw
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
35a7fksjfhrnfwwjl6ln
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
nngkllhiyr9c ghcr
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
6-K
EX-99.1
g8sjd
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
4ca ani02q203u
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.2
q8ibkl4x
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.1
9hgt7p 1opr9bviy9qd
1 Jun 23
Current report (foreign)
4:24pm
6-K
EX-99.1
7zekntc
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
5jpds ab8iduyn1wxtze
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
g04zjr
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
6-K
EX-99.1
s1fq htqd9smefyxc
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
6-K
3sn vz8hkhiv210
30 Aug 22
Current report (foreign)
4:01pm
6-K
EX-99.1
iebeu9y2qprow5y26b8r
16 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.1
ln60027a g6uk
5 Jun 23
Current report (foreign)
4:28pm